Core Historical Cash Flow
| CLB Stock | USD 16.94 0.13 0.76% |
Analysis of Core Laboratories cash flow over time is an excellent tool to project Core Laboratories future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 29.9 M or Depreciation of 21.8 M as it is a great indicator of Core Laboratories ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Core Laboratories latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Core Laboratories is a good buy for the upcoming year.
Core |
About Core Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Core balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Core's non-liquid assets can be easily converted into cash.
Core Laboratories Cash Flow Chart
Core Cash Flow Statement became part of mandatory reporting in 1987. It is now one of three main statements in accounting used to measure how well a company manages its liquidity and overall cash position. The rate of cash utilization and preservation is now part of the leading indicators of a healthy entity, and the Core Laboratories Cash Flow Statement shows how well the company generates cash to payout debt obligations or to cover ongoing operating expenses.
At present, Core Laboratories' Begin Period Cash Flow is projected to decrease significantly based on the last few years of reporting. The current year's Depreciation is expected to grow to about 21.8 M, whereas Change To Inventory is projected to grow to (12.3 M). Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Core Laboratories to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Core Laboratories operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Core Laboratories' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Core Laboratories current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Core Laboratories NV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. At present, Core Laboratories' Begin Period Cash Flow is projected to decrease significantly based on the last few years of reporting. The current year's Depreciation is expected to grow to about 21.8 M, whereas Change To Inventory is projected to grow to (12.3 M).
Core Laboratories cash flow statement Correlations
Click cells to compare fundamentals
Core Laboratories Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Core Laboratories cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (3.9M) | 1.5M | (4.5M) | (14.9M) | (13.0M) | (12.3M) | |
| Change In Cash | (2.0M) | 2.7M | 3.9M | (2.3M) | (308.0K) | (292.6K) | |
| Free Cash Flow | 67.3M | 46.0M | 23.0M | 14.7M | 14.2M | 13.5M | |
| Change In Working Capital | (10.8M) | 35.1M | (11.5M) | (9.6M) | (28.8M) | (27.3M) | |
| Begin Period Cash Flow | 13.1M | 11.1M | 13.8M | 17.7M | 15.4M | 29.9M | |
| Other Cashflows From Financing Activities | 8K | (1.8M) | 153.6M | 113.4M | (54.0K) | (51.3K) | |
| Depreciation | 22.6M | 20.9M | 18.5M | 17.2M | 15.8M | 21.8M | |
| Other Non Cash Items | (478K) | 103.7M | (15.8M) | (10.5M) | 72.0M | 75.6M | |
| Dividends Paid | 97.6M | 12.4M | 1.8M | 1.9M | (1.9M) | (2.0M) | |
| Capital Expenditures | 22.3M | 11.9M | 13.5M | 10.2M | 10.6M | 10.1M | |
| Total Cash From Operating Activities | 89.5M | 57.9M | 36.6M | 25.0M | 24.8M | 23.5M | |
| Net Income | 93.7M | (96.9M) | 20.2M | 19.7M | 36.7M | 34.8M | |
| Total Cash From Financing Activities | (85.9M) | (63.0M) | (22.5M) | (23.4M) | (18.4M) | (19.4M) | |
| End Period Cash Flow | 11.1M | 13.8M | 17.7M | 15.4M | 15.1M | 14.4M | |
| Stock Based Compensation | 20.9M | 7.4M | 19.1M | 7.8M | 14.0M | 14.2M | |
| Other Cashflows From Investing Activities | 16.6M | 19.7M | 2.4M | 6.4M | 5.7M | 6.0M | |
| Change To Liabilities | 1.3M | (29.6M) | 6.6M | 3.6M | 3.3M | 2.7M | |
| Change To Account Receivables | (3.2M) | 46.4M | (13.5M) | (10.1M) | (2.6M) | (2.5M) | |
| Sale Purchase Of Stock | (3.3M) | (2.8M) | (8.3M) | (3.9M) | (2.2M) | (2.3M) | |
| Total Cashflows From Investing Activities | (5.7M) | 7.9M | (10.2M) | (3.9M) | (4.4M) | (4.7M) | |
| Change Receivables | (3.2M) | 46.4M | (13.5M) | (10.1M) | (11.6M) | (11.0M) | |
| Net Borrowings | 15M | (47.5M) | (71M) | (17.2M) | (15.5M) | (14.7M) | |
| Cash And Cash Equivalents Changes | (2.0M) | 2.7M | 3.9M | (2.3M) | (2.6M) | (2.7M) | |
| Cash Flows Other Operating | (1.2M) | 122.1M | (316K) | (3.3M) | (3.8M) | (3.6M) | |
| Change To Netincome | (28.1M) | (5.8M) | 9.8M | 12.7M | 11.4M | 9.8M | |
| Investments | (5.7M) | 7.9M | (10.2M) | (3.9M) | (4.4M) | (4.7M) | |
| Change To Operating Activities | 8.6M | (21.2M) | (11.4M) | (13.6M) | (12.3M) | (11.7M) |
Pair Trading with Core Laboratories
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Core Laboratories position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Core Laboratories will appreciate offsetting losses from the drop in the long position's value.Moving together with Core Stock
| 0.91 | NR | Newpark Resources Financial Report 7th of May 2024 | PairCorr |
| 0.73 | TS | Tenaris SA ADR Downward Rally | PairCorr |
Moving against Core Stock
| 0.57 | NOA | North American Const | PairCorr |
The ability to find closely correlated positions to Core Laboratories could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Core Laboratories when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Core Laboratories - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Core Laboratories NV to buy it.
The correlation of Core Laboratories is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Core Laboratories moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Core Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Core Laboratories can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Core Laboratories NV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Core Stock analysis
When running Core Laboratories' price analysis, check to measure Core Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Core Laboratories is operating at the current time. Most of Core Laboratories' value examination focuses on studying past and present price action to predict the probability of Core Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Core Laboratories' price. Additionally, you may evaluate how the addition of Core Laboratories to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is Core Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Core Laboratories. If investors know Core will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Core Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.35 | Dividend Share 0.04 | Earnings Share 0.51 | Revenue Per Share 10.935 | Quarterly Revenue Growth 0.01 |
The market value of Core Laboratories is measured differently than its book value, which is the value of Core that is recorded on the company's balance sheet. Investors also form their own opinion of Core Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Core Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Core Laboratories' market value can be influenced by many factors that don't directly affect Core Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Core Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Core Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Core Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.